Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium

By sjmartinez • May 10, 2025

Jhaveri K, Anders CK, Bardia A, Bhave M, Chien AJ, Krop I, Traina TA, Abdou Y, Basho R, Conlin AK, Esteva FJ, Fox KR, Gadi V, Kaufman PA, Litvak A, Ma CX, Mamounas EP, McArthur H, McCann K, Mitri Z, Shatsky R, Telli M, Torres MA, Kalinsky K. Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium. Clin Breast Cancer. 2025 Apr 8:S1526-8209(25)00098-9. doi: 10.1016/j.clbc.2025.04.007. Epub ahead of print. PMID: 40340127.

Tags: AKTi, Antibody-drug conjugates, Breast cancer diagnosis, Breast cancer treatment, CDK4/6i, Hematology/Oncology, Publications, unmet needs

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan[...]